These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 26883193

  • 1. Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.
    Creedon H, Gómez-Cuadrado L, Tarnauskaitė Ž, Balla J, Canel M, MacLeod KG, Serrels B, Fraser C, Unciti-Broceta A, Tracey N, Le Bihan T, Klinowska T, Sims AH, Byron A, Brunton VG.
    Oncotarget; 2016 Mar 08; 7(10):11539-52. PubMed ID: 26883193
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani B, Parsons SJ, De Placido S, Bianco R.
    Breast Cancer Res; 2014 May 05; 16(3):R45. PubMed ID: 24887236
    [Abstract] [Full Text] [Related]

  • 3. HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.
    Tracey N, Creedon H, Kemp AJ, Culley J, Muir M, Klinowska T, Brunton VG.
    Breast Cancer Res Treat; 2020 Feb 05; 179(3):543-555. PubMed ID: 31705351
    [Abstract] [Full Text] [Related]

  • 4. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
    Brown WS, Akhand SS, Wendt MK.
    Oncotarget; 2016 Dec 13; 7(50):83424-83436. PubMed ID: 27825137
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH, Ito K, Olcott W, Katsyv I, Halstead-Nussloch G, Irie HY.
    Breast Cancer Res; 2015 Jun 19; 17(1):86. PubMed ID: 26084280
    [Abstract] [Full Text] [Related]

  • 7. Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer.
    Liu J, Chen X, Ward T, Mao Y, Bockhorn J, Liu X, Wang G, Pegram M, Shen K.
    Int J Biochem Cell Biol; 2016 Feb 19; 71():12-23. PubMed ID: 26643609
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L.
    Oncotarget; 2015 Nov 10; 6(35):37269-80. PubMed ID: 26452030
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells.
    Huang WC, Hung CM, Wei CT, Chen TM, Chien PH, Pan HL, Lin YM, Chen YJ.
    Oncotarget; 2016 Sep 20; 7(38):62352-62363. PubMed ID: 27694691
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Testican-1-mediated epithelial-mesenchymal transition signaling confers acquired resistance to lapatinib in HER2-positive gastric cancer.
    Kim HP, Han SW, Song SH, Jeong EG, Lee MY, Hwang D, Im SA, Bang YJ, Kim TY.
    Oncogene; 2014 Jun 19; 33(25):3334-41. PubMed ID: 23873022
    [Abstract] [Full Text] [Related]

  • 14. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
    Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.
    Mol Cancer Ther; 2012 Sep 19; 11(9):1978-87. PubMed ID: 22761403
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X, Wong J, Sevinsky CJ, Kokabee L, Khan F, Sun Y, Conklin DS.
    Mol Cancer Ther; 2016 Sep 19; 15(9):2198-208. PubMed ID: 27256378
    [Abstract] [Full Text] [Related]

  • 17. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
    Chihara Y, Shimoda M, Hori A, Ohara A, Naoi Y, Ikeda JI, Kagara N, Tanei T, Shimomura A, Shimazu K, Kim SJ, Noguchi S.
    Breast Cancer Res Treat; 2017 Nov 19; 166(1):55-68. PubMed ID: 28702892
    [Abstract] [Full Text] [Related]

  • 18. Phosphoproteomic analysis reveals PAK2 as a therapeutic target for lapatinib resistance in HER2-positive breast cancer cells.
    Chang Y, Park KH, Lee JE, Han KC.
    Biochem Biophys Res Commun; 2018 Oct 20; 505(1):187-193. PubMed ID: 30243723
    [Abstract] [Full Text] [Related]

  • 19. Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors.
    Lin CH, Pelissier FA, Zhang H, Lakins J, Weaver VM, Park C, LaBarge MA.
    Mol Biol Cell; 2015 Nov 05; 26(22):3946-53. PubMed ID: 26337386
    [Abstract] [Full Text] [Related]

  • 20. Lapatinib.
    Voigtlaender M, Schneider-Merck T, Trepel M.
    Recent Results Cancer Res; 2018 Nov 05; 211():19-44. PubMed ID: 30069757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.